Type 1 Diabetes Trial, Recruiting NCT07155252 Sponsor: Yale University Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT07155252
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who weigh at least 43 kg (about 95 pounds)
  • People who have at least one islet autoantibody (a marker in the blood that can indicate the immune system is affecting the pancreas), and/or have been diagnosed with clinical Type 1 diabetes within the last 100 days
  • There must be a record confirming the presence of at least one islet autoantibody
  • People who have been diagnosed with Stage 3 Type 1 diabetes may be eligible if the diagnosis was made within the last 100 days and they are at least 12 years old
  • People who are in generally good health, without other serious ongoing or recent illnesses that the trial doctor believes could affect their safety or the study results
  • People who are able to give their own consent (or assent, for younger participants)
  • People who can read and understand written and spoken English

Who may not be able to join:

  • People who are currently pregnant, or who become pregnant during the study
  • People who are currently taking a type of medication known as sodium glucose cotransporter inhibitors (SGLTi) — a group of medicines sometimes used to manage blood sugar levels (confirm with trial site if unsure whether a current medication falls into this category)
  • People who have donated blood in the past 8 weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jennifer Sherr, MD, Yale University

Phone: 203-737-4805

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
26 August 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Accuracy of GTT@Home

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov